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VEGFThe pharmacological modulation of renoprotective factor vascular endothelial growth factor-A (VEGF-A) in
the proximal tubule has therapeutic interest. In human proximal tubular HK-2 cells, treatment with
all-trans retinoic acid or prostaglandin E2 (PGE2) triggers the production of VEGF-A. The pathway involves
an initial increase in intracellular PGE2, followed by activation of EP receptors (PGE2 receptors, most
likely an intracellular subset) and increase in retinoic acid receptor-β (RARβ) expression. RARβ then
up-regulates transcription factor hypoxia-inducible factor-1α (HIF-1α), which increases the transcription
and production of VEGF-A. Here we studied the role in this pathway of epidermal growth factor receptor
(EGFR) transactivation by EP receptors. We found that EGFR inhibitor AG1478 prevented the increase in
VEGF-A production induced by PGE2- and all-trans retinoic acid. This effect was due to the inhibition of
the transcriptional up-regulation of RARβ, which resulted in loss of the RARβ-dependent transcriptional
up-regulation of HIF-1α. PGE2 and all-trans retinoic acid also increased EGFR phosphorylation and this effect
was sensitive to antagonists of EP receptors. The role of intracellular PGE2 was indicated by two facts;
i) PGE2-induced EGFR phosphorylation was substantially prevented by inhibitor of prostaglandin uptake
transporter bromocresol green and ii) all-trans retinoic acid treatment, which enhanced intracellular but
not extracellular PGE2, had lower effect on EGFR phosphorylation upon pre-treatment with cyclooxygenase
inhibitor diclofenac. Thus, EGFR transactivation by intracellular PGE2-activated EP receptors results in the
sequential activation of RARβ and HIF-1α leading to increased production of VEGF-A and it may be a target
for the therapeutic modulation of HIF-1α/VEGF-A.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Critical mediators of cellular adaptation to hypoxia are hypoxia-
inducible factors (HIFs), HIF-1 and HIF-2 being the most prominent
and best characterized. HIF is a transcription factor that consists of
an oxygen-sensitive α-subunit, HIF-α and a constitutively expressed
β-subunit, HIF-β. In a hypoxic environment HIF-α is stabilized and
translocates to the nucleus, and, together with the β subunit and tran-
scriptional coactivators, it binds to hypoxia-responsive elements
(HRE) in target genes [1]. HIF-1α supports tissue survival in hypoxia
by regulating the expression of gene products that are involved in2; EPR, EP receptors; RARβ,
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rights reserved.cellular energy metabolism, angiogenesis, erythropoiesis and other
biological processes [2]. These products include enzymes involved in
glucose uptake and metabolism, carbonic anhydrase IX, erythropoie-
tin and vascular endothelial growth factor (VEGF) [3]. HIF-1α expres-
sion is also increased in normoxia: growth and coagulation factors,
hormones, stress factors and inﬂammatory mediators such as prosta-
glandin E2 (PGE2), cytokines, interleukin-1β, tumor necrosis factor-α,
nitric oxide and reactive oxygen species increase the expression of
HIF-1α [4,5]. They increase HIF-1α transcription and/or translation
[4,6] but not HIF-1α protein stability.
All-trans retinoic acid (ATRA) is the carboxylic acid form of vitamin
A and its major metabolite. The actions of ATRA are generally mediated
by binding to retinoic acid receptors (RARs), which are members of the
nuclear receptor superfamily. RARs are key regulators of multiple phys-
iological processes, most signiﬁcantly embryonic development and
organ homeostasis. At the cellular level, RARs contribute to the regula-
tion of gene networks that control cell growth, differentiation, survival
and death [7]. Three RAR subtypes (RARα, RARβ and RARγ) have
been identiﬁed. They act as ligand-regulated transcription factors by
dimerizing with retinoid X receptors (RXR) and binding to retinoic
2030 A.B. Fernández-Martínez, F.J. Lucio Cazaña / Biochimica et Biophysica Acta 1833 (2013) 2029–2038acid response elements (RARE), which are located in the regulatory
regions of their target genes [8]. RARβ itself is a RARs target [9]: its
promoter region contains a RARE (β-RARE) responsible for the up-
regulation of RARβ induced by ATRA in many different cell types [10].
We have recently shown in human renal proximal tubular HK-2
cells that the up-regulation of RARβ by cyclooxygenase (COX)-
dependent production of PGE2 plays a critical role in the increase in
HIF-1α expression induced by ATRA, interleukin-1β, PGE2 analogue
16,16-dimethyl-PGE2 (16,16-PGE2) or hypoxia [11,12]. Interestingly,
the transcriptional inhibitor actinomycin D prevented the increase
in RARβ and HIF-α expression induced in normoxia but not in hypox-
ia [13].
It is accepted that, once prostanoids are formed, they are quickly
released to the outside of cells by simple diffusion and act as auto-
crine or paracrine mediators in the vicinity of their sites of production
to maintain local homeostasis [14–17]. Therefore, it has generally
been assumed that PGE2 exerts its actions via plasma membrane
spanning G-protein coupled EP receptors (EPR: EP1, EP2, EP3 and
EP4), each EP activating a distinct G protein-coupled signaling path-
way [14,15]. However, the up-regulation of RARβ in HK-2 cells by
HIF-1α-increasing agents was most likely due to intracellular EPR
activated by intracellular PGE2 (iPGE2) [12]. These data are in good
agreement with the location of functional EPR at the nuclear mem-
branes of a variety of cell types and tissues [18–20]. In fact, in HK-2
cells the four EPR are located not only in the cell membrane but also
inside the cell [11]. We have also provided data on the regulation of
RARβ expression by iPGE2 in other cell lines, which indicates that it
is not a phenomenon restricted to HK-2 cells [12]. It is important to
take into account that the classical downstream plasma membrane
EPR-linked signaling cascades pathways activated by PGE2 may not
necessarily be the same ones linked to iPGE2-activated intracellular
EPR. For instance: it has been proposed that iPGE2, acting through in-
tracellular EP4 receptors, maintains epidermal growth factor receptor
(EGFR) in an activated state in cardiac myocytes [21]. This activation
of EGFR through a molecule that does not, itself, bind EGFR is called
transactivation.
The elucidation of the mechanism through which iPGE2-activated
EPR increase RARβ expression has important implications. For in-
stance, the up-regulation of the RARβ gene by ATRA presumably
plays a critical role in amplifying the ATRA response [10]. In our
more speciﬁc context, we have shown that the increase in the expres-
sion of HIF-1α through this pathway enhances the production of
VEGF-A, a putative renoprotective factor [12]. In the present work
we have investigated the role of EGFR in the iPGE2-dependent path-
way leading to the increase in VEGF-A production under normoxic
conditions. We have found that the transactivation of EGFR by
iPGE2-activated EPR (upon treatment with 16,16-PGE2 or ATRA)
plays a crucial role in the transcriptional up-regulation of RARβ and
that the increase in RARβ expression led, in turn, to the transcription-
al up-regulation of HIF-1α and, eventually, to the increase in the pro-
duction of VEGF-A.Table 1
TaqMan® probes table.
Gene Applied Biosystems ref.
HIF-1α Hs00936368m1
RARβ Hs00977140m1
GAPDH Hs03929097g12. Material and Methods
2.1. Reagents
16,16-PGE2, bromocresol green, diclofenac, AH6809 andGW627368X
were purchased from Cayman Chemical (Ann Arbor, MI). AG1478,
actinomycin D, YC1 and ATRA were purchased from Sigma (St. Louis,
MO). RARβ antagonist LE135 was a generous gift from Prof. Hiroyuki
Kagechika (Tokyo Medical and Dental University, Japan). Primary anti-
bodies against RARβ and phospho-EGFR were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibody against HIF-1αwas pur-
chased from BD Biosciences (Palo Alto, CA) and anti-β-actin antibody
was from Sigma Chemical Co. (St. Louis, MO).2.2. Cell culture and treatments
Human kidney HK-2 cells, human prostate cancer cells (PC3) and
human renal cell carcinoma (A498) were purchased from American
Type Culture Collection (Rockville, MD). HK-2 were maintained in
DMEM/F12 supplemented with 10% foetal bovine serum (FBS), 1%
penicillin/streptomycin/amphoterycin B and 1% glycine (Invitrogen,
Carlsbad, CA) and 1% Insulin–Transferrine–Selenium (Sigma, St. Louis,
MO). PC3 were maintained in RPMI and A498 cells were maintained
in MEM Eagle, and supplemented with 10% FBS and 1% penicillin/
streptomycin/amphoterycin B.
The culture was performed in a humidiﬁed 5% CO2 environment at
37 °C. In all experiments, cells were plated at 70–90% conﬂuence and
24 h later they were treated with 1 μM 16,16-PGE2 and/or 10 μM
ATRA, for different periods of time. When appropriated, the following
agents were added 1 h before: 50 μM bromocresol green (inhibitor of
prostaglandin uptake transporter), 0.3 mM diclofenac (COX inhibi-
tor), 10 μM AH6809 (antagonist of EP1-3 receptors) or GW627368X
(antagonist of EP4 receptor), 1 μg/ml actinomycin D (transcription in-
hibitor), 2 μM LE135 (RARβ antagonist), 10 μMYC1 (HIF-1α inhibitor),
1 μM AG1478 (inhibitor of EGFR activation) were added 1 h before the
treatment.
2.3. Real-time quantitative RT-PCR
Total cell RNA from HK-2 cells was isolated with TriReagent (Sigma,
St. Louis, MO). One microgram of total RNA, extracted by using the
TaqMan® Gene Expression Master Mix (Applied Biosystems), was
reverse transcribed in a total reaction volume of 25 μl bymeans of incu-
bation at 42 °C for 30 min using random hexamer primers. For quanti-
tative PCR, mRNAs were ampliﬁed and quantiﬁed by TaqMan probes
(Applied Biosystems) (Table 1). As template, cDNA from the target
and housekeeping gene GAPDH were prepared in separate tubes for
each primer master mixture reaction. The comparative threshold cycle
(CT) method was used to calculate the relative expression [22].
2.4. Protein isolation and Western-blotting
HK-2 cells were stimulated and washed twice with ice-cold PBS and
then harvested, scraped into ice-cold PBS, and then pelleted by centrifu-
gation at 500 ×g, for 5 min, at 4 °C. Cells were kept on ice for 30 min in
a solution containing 50 mMTris–HCl (pH7.5), 150 mMNaCl, 1% Triton
X-100, 0.5% sodium deoxycholate and protease inhibitors. Thereafter,
the cells were pelleted by centrifugation at 4000 ×g, for 5 min, at
4 °C. Proteins from cell lysates were denatured by heating. Then, they
were resolved by 10% SDS-PAGE, and blotted onto a nitrocellulose
membrane (BioTrace/NT), for 1 h, in 50 mMTris–HCl, 380 mMglycine,
0.1% SDS, and 20% methanol. Blots were incubated overnight at 4 °C
with rabbit anti-RARβ (1:1000), mouse anti-HIF-1α (1:1000) and
rabbit anti-phospho-EGFR (1:500) antibodies. After treatment for 1 h
at room temperature with the corresponding secondary antiserum
(1:4000), the signals were detectedwith enhanced chemiluminescence
reagent using β-actin antibody (1: 25000) as loading control.
2.5. Determination of PGE2 formation
PGE2 was determined in culture medium and cell lysates using a
commercially available enzyme immunoabsorbent assay (EIA) kit
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facturer's protocol.2.6. Determination of VEGF secretion
HK-2 cells were placed in 24 well plates (7.5 × 104 cells/well) for
24 h. Then they were treated as indicated in Fig. 4c and d and the medi-
umwas removed and kept at−80 °C. VEGFwas analyzed by ELISA assay
using a human VEGF Human Development Kit (Tebu-bio, Le-Perray-en-
Yvelines, France).2.7. Plasmids, siRNA, transient transfection and luciferase assay
Transient transfection with luciferase reporter plasmid tk-β-RARE-
Luc (the plasmid, which contains a part of the RARE sequence from
the promoter of the human RARβ gene, was a generous gift of Prof.
Ronald Evans, The Salk institute, CA, USA) or luciferase reporter plasmid
p9HIF1-Luc (the plasmid, which contains nine copies of a part of the
human HIF binding sequence of the 5′ human VEGF gene promoter
was generously gifted by Dr. Manuel Ortiz de Landazuri, Servicio de
Inmunología, Hospital de La Princesa, Madrid, Spain) or luciferase re-
porter plasmid RARβ 2-tk-luc reporter (which was made by cloning
the RARβ promoter in a pre-existing tk-luc plasmid, was a generous
gift Rene Bernard, Division of Molecular Carcinogenesis and Center for
Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam,
The Netherlands) was performed as follows: 3 × 105 cells per well
were plated in 6-well plates 24 h before transfection. Cells were incu-
bated 12 h at 37 °C with 1 ml OptiMEM (Invitrogen, CA) containing
complexes of 5 μg lipofectamine (Invitrogen, CA), 1 μg human tk-ß-
RARE-Luc or p9HIF1-Luc or RARβ2-tk-luc reporter and 1 μg renilla lucif-
erase reporter as an internal control. Transfected cells were next incu-
bated with complete growth medium for 24 h and then pretreated
with different drugs for 1 h and treated either 16,16-PGE2 or ATRA for
4 h. Finally, ﬁreﬂy luciferase activity was measured with a Lumat
LB9506 luminometer (Berthold Technologies, Herts, UK) and normal-
ized against renilla luciferase activity by using the dual-luciferase
reporter assay system (Promega, Madison, WI).
For inhibiting HIF-1α and RARβ expression, we used HIF-1α siRNA
sc-44225 and RARβ siRNA (sc-29466) (Santa Cruz Biotechnologies),
respectively, and scramble siRNA AM4637 (Applied Biosystems) as a
control. HK-2 cells at 70% conﬂuence were transfected with 100 nM
RARβ, HIF-1α siRNA or scramble siRNA using Lipofectamine 2000
reagent. Twenty four hours after transfection, cells were used for the
experiments.2.8. Immunoﬂuorescence
Cells were ﬁxed for 20 min with ice-cold methanol following 1 h of
blocking at room temperature. Blocking solution (4 % BSA in PBS) was
further used for dilution of primary and secondary antibodies. Next
cells were incubated at 4 °C with primary anti-phospho EGFR antibody
diluted 1:50 for overnight following PBS washing and for 1 h with sec-
ondary antibody (Alexa FLUO 488 goat 1:1000) following PBS washing.
Finally coverslips were mounted with ProLong Gold antifade reagent
with DAPI (Invitrogen). The detection was performed by confocal
laser scan microscopy LEICA TCS-SL (Heidelberg, Germany).2.9. Statistical analysis
Each experiment was repeated at least three times. The results are
expressed as the mean ± SD. They were subjected to one way analysis
of variance (ANOVA) following by the Bonferroni's test for multiple
comparisons. The level of signiﬁcance was set at P b 0.05.3. Results
3.1. PGE2-induced RARβ up-regulation is due to increased RARβ mRNA
transcription by iPGE2. Role of RARE and EPR
Transcriptional mechanisms are responsible for the up-regulation of
RARβ by ATRA [7]. Therefore,we hypothesized that the up-regulation of
RARβ by iPGE2 was due to an increase in the expression of RARβmRNA.
In order to test this hypothesis, we ﬁrst investigated whether inhibition
of transcription prevented PGE2-induced RARβ protein up-regulation.
To this end, the expression of RARβ protein and mRNA was assessed
by Western blot and Q-RT-PCR, respectively, in HK-2 cells which were
ﬁrst incubated for 1 hwith orwithout transcription inhibitor actinomy-
cin D and then with 16,16-PGE2. 16,16-PGE2-induced increase in RARβ
protein and mRNA expression was abolished by actinomycin D (Fig. 1a
and b), which suggested that transcriptional mechanisms were respon-
sible for the up-regulation of RARβ by 16,16-PGE2. Finally, when cells
were incubated ﬁrst with 16,16-PGE2 and then with actinomycin D
for up to 4 h in order to determine the RARβ mRNA half-life, we
found no differences between 16,16-PGE2-treated cells and control
cells (Fig. 1b, inset). These results indicate that transcriptional mecha-
nisms, but not post-transcriptional ones, are involved in 16,16-PGE2-
induced RARβ up-regulation.
We next analyzed the effect of 16,16-PGE2 on the activity of the
RARβ gene promoter. HK-2 cells were transiently transfected with ei-
ther tk-β-RARE-Luc (RARE construct from the RARβ gene) or a con-
struct of the whole RARβ promoter. The treatment with 16,16-PGE2
resulted in an increase in the luciferase activity of the RARE and
RARβ promoter constructs (Fig. 1c) as well as in the expression of
RARβmRNA (Fig. 1d). Furthermore, the time-course of the activation
of RARE-Luc in HK-2 cells (Fig. 1c, inset), was compatible with its
participation in the up-regulation of RARβ mRNA by 16,16-PGE2. In-
creased luciferase activity upon treatment with 16,16-PGE2 was also
observed in human prostate cancer cells PC3 and human renal cell
carcinoma A498 cells (Fig. 1c). This suggests that the induction of
RARE activity by 16,16-PGE2 might be a widespread effect of the
prostanoid and not a phenomenon restricted to HK-2 cells.
To conﬁrm that the transcriptional effects of 16,16-PGE2 on RARβ
expression were actually due to iPGE2, we analyzed the effect of the
inhibition of prostaglandin uptake by pre-treatment for 1 h with
50 μM bromocresol green (BG). BG prevented (Fig. 1e) the increase in
RARE-Luc activity, RARβ promoter activity (inset) and RARβ mRNA
expression induced by 16,16-PGE2.
Finally, we assessed the effect of antagonist of EP1-EP3 receptors
AH6809 [23] or antagonist of EP4 receptor GW627368X [24] on
16,16-PGE2-induced increase in RARE-Luc activity and expression of
RARβ mRNA. As shown in Fig. 1f, preincubation for 1 h with these
antagonists blocked the increase in RARE-Luc activity and the up-
regulation of RARβ mRNA induced by 16,16-PGE2.
In summary, the results shown in Fig. 1 support the view that the
transcriptional up-regulation of RARβ by iPGE2-activated EPR (most
likely through RARE activation) is responsible for 16,16-PGE2-induced
increase in RARβ protein expression.
3.2. iPGE2, in an EPR antagonist sensitive manner, mediates the
transcriptional increase of RARβ expression induced by ATRA
We next analyzed the implication of iPGE2 in the transcriptional
up-regulation of RARβ by ATRA.
In HK-2 cells, iPGE2 increases upon treatment with ATRA (Fig. 2a),
while the release of PGE2 to the extracellular medium, compared to
control cells, actually diminishes. Consequently, ATRA-induced in-
crease in iPGE2 would not be sensitive to BG. Instead, it is adequately
prevented by a COX inhibitor such is diclofenac (Fig. 2a).
We next assessed the effect on ATRA-induced increase in RARβ
mRNA and RARE-Luc activity of pre-incubation for 1 h with 0.3 mM
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Fig. 2. iPGE2, in an EPR antagonist-sensitive manner, mediates the transcriptional increase of RARβ expression induced by ATRA. a) Treatment with ATRA increases the intracellular
content in PGE2 but not the release of PGE2 to the extracellular medium. HK-2 cells were incubated for 1 h with 0.3 mM diclofenac or in control conditions and then they were
treated with 10 μM ATRA for 24 h. PGE2 levels were measured by EIA in the culture medium and in cell lysates. b) ATRA increases RARβ mRNA expression in a diclofenac- and
EPR antagonist-sensitive manner. HK-2 cells were incubated for 1 h with 0.3 mM diclofenac, 10 μM AH6809 or with 10 μM GW627368X and then with 10 μM ATRA for 4 h.
c) ATRA increases RARE activity in a diclofenac- and EPR antagonist-sensitive manner. HK-2 cells (left panel), PC3 cells and A498 cells (right panel) were transiently transfected
with RARE-Luc plasmid construct. Then, they were pre-incubated with diclofenac or EPR antagonists and incubated with ATRA as in b). d) ATRA and 16,16-PGE2 do not synergize
to increase RARE-Luc activity. HK-2 cells were transfected as in c) and treated for 4 h with ATRA or/and 16,16-PGE2. General information: 1) Reporter gene experiments: Luciferase
activity was normalized by Renilla luciferase activity and expressed as relative luminescence units (RLU). 2) Bars and error bars in graphs: Each bar represents the mean ± SD of 3
different experiments. *P b 0.05 vs. control.
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AH6809 or 10 μM antagonist of EP4 receptor GW627368X: the three
agents tested blocked both increases (Fig. 2b and c, left panel). Of
note, we conﬁrmed that diclofenac, AH6809 and GW627368X also
prevented ATRA-induced increase in RARE-Luc activity in PC3
and A498 cell lines (Fig. 2c, right panel). We ﬁnally studied in HK-2
cells whether ATRA and 16,16-PGE2 synergized to over-increaseFig. 1. PGE2-induced RARβ up-regulation is due to increased RARβmRNA transcription by iP
protein up-regulation. HK-2 cells were incubated for 1 h with/without 1 μg/ml actinomycin
mRNA up-regulation is prevented by inhibition of transcription. Cells were incubated as a
Q-RT-PCR. Inset: Cells were incubated for 4 h with/without 1 μM 16,16-PGE2 and treated w
creases the activity of human retinoic acid-responsive element (RARE)-Luc and RARβ-Luc co
(A498) were transiently transfected with the plasmid constructs and incubated for 4 h with
HK-2 cells. d) 16,16-PGE2 induces RARβ mRNA up-regulation. HK-2 cells were incubated w
e) Inhibition of prostaglandin uptake prevents 16,16-PGE2-induced increase in the activi
transfected with the constructs were incubated with bromocresol green (50 μM/1 h) and
activity and RARβ mRNA induced by 16,16-PGE2. HK-2 cells were preincubated for 1 h with
of EPR4) and then with 1 μM 16,16-PGE2 for 4 h. General information: 1) Western blot exper
the results is shown. 2) Reporter gene experiments: Luciferase activity was normalized by Re
error bars in graphs: Each bar represents the mean ± SD of 3 different experiments. *P b 0the activity of RARE-Luc. Our results (Fig. 2d) excluded this pos-
sibility, which suggests that ATRA activates RARE through the
same mechanism responsible for 16,16-PGE2-induced RARE-Luc
activity.
Since ATRA is the physiological activator of RARE, the results
shown in Fig. 2 conﬁrm the critical role of iPGE2 in the transcriptional
up-regulation of RARβ.GE2. Role of RARE and EPR. a) Inhibition of transcription prevents PGE2-induced RARβ
D (actD) and then for 8 h with/without 1 μM 16,16-PGE2. b) 16,16-PGE2-induced RARβ
bove for 4 h. Total cell RNA was extracted and RARβ mRNA levels were analyzed by
ith 1 μg/ml act D for 0 to 4 h to analyze the decay of RARβ mRNA. c) 16,16-PGE2 in-
nstructs. HK-2 cells, human prostate cancer cells (PC3) and human renal cell carcinoma
or without 1 μM 16,16-PGE2. Inset: Time-course of RARE activity in 16,16-PGE2-treated
ith 1 μM 16,16-PGE2 for up to 8 h and RARβ mRNA levels were analyzed by Q-RT-PCR.
ty of RARE-Luc and RARβ-Luc constructs and in RARβ mRNA expression. HK-2 cells
then with PGE2 (1 μM/4 h). f) Antagonists of EP receptors block the increase in RARE
10 μM AH6809 (an antagonist of EPR1-3) or with 10 μM GW627368X (an antagonist
iments: Each experiment was repeated three times and a representative photograph of
nilla luciferase activity and expressed as relative luminescence units (RLU). 3) Bars and
.05 vs. control.
Fig. 3. EP receptor-dependent EGFR transactivation is responsible for iPGE2-induced RARβ up-regulation. a) ATRA and 16,16-PGE2 induce EGFR phosphorylation. HK-2 cells were incubated for
up to 45 min with 10 μMATRA or 1 μM PGE2 and phosphorylation of EGFR was assessed byWestern blot or immunoﬂuorescence analysis (photographs, taken after 30–45 min are shown).
b) 16,16-PGE2- and ATRA-induced EGFR phosphorylation are prevented by inhibition of the increase in iPGE2- and antagonism of EPR. HK-2 cells were preincubated for 1 h with 50 μM
bromocresol green, 0.3 mM diclofenac, 10 μM AH6809 or 10 μM GW627368X and then for 30 min with either 1 μM 16,16-PGE2 or 10 μM ATRA. Normalized density ratio of EGFR-P over
β-actin is indicated for each band. c) ATRA- and 16,16-PGE2-induced increase in RARE-Luc activity and RARβmRNA and protein expression are prevented by inhibitor of EGFR phosphorylation
AG1478. Cellswere pre-incubated for 1 hwith 1 μMAG1478 and thenwith 10 μMATRAor 1 μM16,16-PGE2 for 4 h. d) ATRA- and16,16-PGE2-induced increase in RARE-Luc activity in PC3 and
A498 cell lines is prevented by AG1478. Cells transfected with RARE-Luc plasmid construct were treated as in c). General information: 1) Western blot: Each experiment was repeated three
times and a representative photograph of the results is shown. 2) Reporter gene experiments: Luciferase activity was normalized by Renilla luciferase activity and expressed as relative lumi-
nescence units (RLU). 3) Bars and error bars in graphs: Each bar represents the mean ± SD of 3 different experiments. *P b 0.05 vs. control. **P b 0.05 vs. GW627368X.
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iPGE2-induced RARβ up-regulation
We next investigated the role of EGFR in the up-regulation of
RARβ. To this aim, we ﬁrst studied the time-course of the phosphor-
ylation of EGFR in HK-2 cells incubated with ATRA or 16,16-PGE2 for
up to 45 min. As seen in Fig. 3a, upper panel, EGFR phosphorylation
increased from the very ﬁrst minutes with both treatments and
remained in high values after 45 min incubation. These results were
conﬁrmed by immunoﬂuorescence analysis: phosphorylated EGFR
was ubiquitous in control HK-2 cells but its nuclear location, as well
as its overall expression, increased upon treatment with ATRA or
16,16-PGE2 (Fig. 3a, lower panel). These changes happened in a man-
ner time-dependent (for clarity we only show the microphotographs
taken after 45 or 30 min treatment).
To analyze the role of iPGE2 in the phosphorylation of EGFR, HK-2
cells were ﬁrst pre-incubated for 1 h with either the inhibitor of pros-
taglandin uptake transporter BG or COX inhibitor diclofenac prior to
treatment with 16,16-PGE2 or ATRA, respectively, and cell levels of
phosphorylated EGFR were assessed byWestern blot analysis. Our re-
sults (Fig. 3b) indicated that BG and diclofenac prevented 16,16-PGE2-
and ATRA-induced EGFR phosphorylation (although the prevention
by BGwas not 100% effective).When cells were preincubatedwith an-
tagonist of EP1-EP3 receptors AH6809 orwith EP4 receptor antagonist
GW627368X, 16,16-PGE2- and ATRA-induced EGFR phosphorylation
were also prevented (GW627368X did not fully prevent ATRA-
induced EGFR phosphorylation, though). These results indicate that
iPGE2-dependent activation of EPR is involved in the mechanism of
16,16-PGE2- and ATRA-induced EGFR transactivation.
To conﬁrm the involvement of transactivation of EGFR in the
iPGE2-dependent increase of RARβ expression, we examined the ef-
fect in HK-2 cells of the inhibitor of EGFR activation AG1478 (1 μM,
1 h pre-incubation) on ATRA- or 16,16-PGE2-induced increase in
RARE-Luc activity (in cells previously transfected with reporter lucif-
erase plasmid tk-β-RARE-Luc) and in RARβ mRNA and protein
expression. Our results (Fig. 3c) indicated that the inhibitor of EGFR
activation AG1478 prevented the whole sequence of events involved
in ATRA- or 16,16-PGE2-induced increase in RARβ expression (and
therefore the RARβ-dependent increase in HIF-1α expression) in
HK-2 cells. Taken together, the results shown in Fig 3a–c indicate
that transactivation of EGFR by iPGE2-activated EPR mediates the
increase in RARβ expression in HK-2 cells.
Since the ﬁrst step in the transcriptional up-regulation of RARβ by
16,16-PGE2 and ATRA involves activation of RARE by iPGE2-activated
EPR (Figs. 1 and 2), we also analyzed the effect of AG1478 in other cell
lines which were transfected with plasmid tk-β-RARE-Luc. As shown
in Fig. 3d induction of RARE-Luc by 16,16-PGE2 and ATRA in PC3 cells
and A498 cells was prevented by AG1478, which suggested that
transactivation of EGFR might be universally required for the activa-
tion of RARE leading to increased expression of RARβ.
3.4. Activation of EGFR and RARβ, leading to transcriptional
up-regulation of HIF-1α, is responsible for iPGE2-induced
production of renoprotective factor VEGF-A.
Taking into account the results shown in Figs. 1 and 3, we hypoth-
esized that iPGE2 enhances the production of renoprotective factor
VEGF-A through an EGFR-, RARβ-dependent transcriptional increase
in HIF-1α expression, leading to activation of the HRE in the VEGF-A
gene promoter. In order to test this hypothesis, we ﬁrst analyzed
the effect of 16,16-PGE2 on the expression of HIF-1α mRNA and
found that it increased by 69.1 ± 9.1% after 4 h incubation (Fig. 4a,
inset). We next sought to conﬁrm that the transcriptional increase
in the expression of HIF-1α was dependent on iPGE2 and RARβ. To
this aim, HK-2 cells were incubated with BG or LE135 (RARβ antago-
nist) prior to incubation with 16,16-PGE2. Our results (Fig. 4a)indicated that the two agents prevented the PGE2-induced increase
in HIF-1α mRNA. Then we examined the involvement of EGFR in
the iPGE2-induced increase in HIF-1α mRNA expression by incubat-
ing cells with AG1478 prior to treatment with 16,16-PGE2 or ATRA.
AG1478 prevented 16,16-PGE2- and ATRA-induced increase in the
expression of HIF-1α mRNA (Fig. 4b). Taking into account that
16,16-PGE2 increases the expression of HIF-1α protein in an actino-
mycin D-sensitive manner (Fig.1a), the results shown in Fig. 4a and
b strongly suggest that up-regulation of HIF-1α is due to EGFR-,
RARβ-dependent increase in HIF-1α mRNA by iPGE2.
We next askedwhether iPGE2-inducedHIF-1α up-regulation results
in activation of the HRE in the VEGF-A gene promoter. We used HK-2
cells transiently transfected with p9HIF1-Luc (a plasmid which
contained part of the human HIF binding sequence of the 5′ human
VEGF gene promoter). Fig. 4c shows that the treatment for 4 h with
1 μM 16,16-PGE2 determined a strong increase in luciferase activity,
which was abolished by BG and YC1 (an inhibitor of HIF-1α [25]). BG
and transfection with HIF-1α siRNA also prevented the increase in the
production of VEGF-A (quantiﬁed by ELISA) in 16,16-PGE2-treated
cells. Finally, to ensure that iPGE2-induced HRE activation and VEGF-A
production were dependent on EGFR and RARβ, we studied in 16,16-
PGE2-treated cells the effect of inhibition of EGFR transactivation with
AG1478 or inhibition of RARβ with RARβ siRNA or RARβ antagonist
LE135. Fig. 4d conﬁrms the dependency of iPGE2-induced HRE activa-
tion and VEGF-A production on the activity of EGFR and RARβ (siRNA
RARβ did not fully prevent 16,16-PGE2-induced VEGF-A production,
which was probably due to the fact that RARβ expression was only
reduced by 67% instead of being fully suppressed).
In summary, the results presented in Fig. 4 depict a scenario in
which iPGE2, acting through EGFR and RARβ, up-regulates HIF-1α
mRNA. This effect eventually leads toHIF-1α-dependentHRE activation
and further increase in production of renoprotective factor VEGF-A in
HK-2 cells.
4. Discussion
We have previously found in HK-2 cells and other cell lines that
intracrine PGE2-EPR signaling plays a critical role in the up-regulation
of RARβ after treatmentwith PGE2 or ATRA [11,12]. Enhanced RARβ ex-
pression, in turn, leads to an increase in both the expression of HIF-1α
and the production of HIF-1α-regulated renoprotective factor VEGF-A
[11,12]. In the present work we have studied the role of EGFR and tran-
scriptional mechanisms in the regulation of VEGF-A production by
iPGE2. Our results indicated that transactivation of EGFR by iPGE2-
activated EPR (presumably an EPR subset located intracellularly [11])
plays a critical role because it mediates the increase in RARβ expression
induced by PGE2 or ATRA. The mechanism involved RARβ mRNA
up-regulation, most likely through activation of the RARE in the RARβ
promoter (Fig. 5). Finally, the increase in VEGF-A production was
found to be due to RARβ-dependent transcriptional up-regulation of
HIF-1α, which most likely resulted in activation of the HRE in the
VEGF-A promoter (Fig. 5).
To the best of our knowledge this is the ﬁrst time ever in which
iPGE2 has been shown to enhance RARβ mRNA expression. EGFR/
EPR-dependent RARE activation upon treatment with 16,16-PGE2 or
ATRA was also demonstrated in other cell lines. Therefore, trans-
activation of EGFR by iPGE2-activated EPR is probably an integral part
(though a newly described one) of the physiological pathway for
ATRA-induced RARE activation in the RARβ promoter leading to RARβ
mRNA up-regulation. There are two relevant questions regarding the
studies on RARE activity. The ﬁrst one is why treatment with EP1/EP2/
EP3 receptor antagonist AH6809 or with EP4 receptor antagonist
GW627368X produced a complete inhibition of the activation of the
RARE-Luc construct from the RARβ gene promoter. Because, if all EPR
were implicated, one could expect that after AH6809 treatment there
should be still response through EP4. Moreover, it could be argued
Fig. 4. Activation of EGFR and RARβ, leading to transcriptional up-regulation of HIF-1α, is responsible for iPGE2-induced production of renoprotective factor VEGF. a)16,16-PGE2-
induced increase in HIF-1a mRNA expression is prevented by inhibition of prostaglandin uptake or antagonism of RARβ. HK-2 cells were preincubated with bromocresol green or
LE135, and incubated with 1 μM 16,16-PGE2 for 4 h (or for 0–4 h in the inset). b) 16,16-PGE2- and ATRA-induced increase in HIF-1α mRNA expression are prevented by AG1478.
HK-2 cells were incubated for 1 h with AG1478 and then with 16,16 PGE2 or ATRA for 4 h. c) Inhibition of prostaglandin uptake and HIF-1α prevent 16,16-PGE2-induced increase in
HRE-Luc activity and VEGF-A production. Left panel: HK-2 cells were transfected with p9HIF1-Luc, preincubated for 1 h with 50 μM bromocresol green or 10 μM YC1 and then,
incubated with 16,16-PGE2 for 4 h. Right panel: Cells were transfected with HIF-1α siRNA, or control siRNA (scramble) or they were pretreated with bromocresol green. Thereafter
cells were incubated with/without 16,16-PGE2 for 48 h and the released VEGF-A was measured by ELISA. d) 16,16-PGE2-induced increase in HRE-Luc activity and VEGF-A produc-
tion are prevented by inhibitors of EGFR phosphorylation and RARβ activity. Left panel: Cells were transfected with p9HIF1-Luc, preincubated for 1 h with 1 μM AG1478 or 2 μM
LE135 and then, incubated with 1 μM 16,16-PGE2 for 4 h. Right panel: Cells were transfected with RARβ siRNA, or control siRNA (scramble) or they were pretreated for 1 h with
1 μM AG1478 or 2 μM LE135. Thereafter cells were incubated with or without 16,16-PGE2 for 48 h. General information: 1) Reporter gene experiments: Luciferase activity was
normalized by Renilla luciferase activity and expressed as relative luminescence units (RLU). 2) Bars and error bars in graphs: Each bar represents the mean ± SD of 3 different
experiments. *P b 0.05 vs. control.
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should be detected. However, we donot think that all EPRs are implicat-
ed in the activation of the RARE. We rather think that RARE activation
needs the simultaneous stimulus from at least two EPRs: one of them,
of course, is EP4 and the other is EP1, EP2 and/or EP3. This would ex-
plain why treatment with AH6809 or GW627368X results in the com-
plete inhibition of RARE activation. The need of simultaneous stimulus
from at least two EPRs to get a biological response is not unusual. For
instance, it has been previously shown that treatment with AH6809 or
AH23848 (an EP4 receptor antagonist) suppress PGE2-induced phos-
phorylation of Akt in HUVEC cells [26].Wewill focus now on the second
question, which arises from the fact that on PC3 cells AG1478 lowers
RARE activity well below the control value. This suggests that in PC3
cells, EGFR activity is responsible not only for iPGE2-induced RAREactivation but also for basal RARE activity. The fact that the pre-
incubation with EGFR inhibitor AG1478 does not reduce the activity of
RARE in PC3 cells treated with ATRA or PGE2 to the level found in cells
which were only treated with AG1478 (comparing column 4 with 5
and 6), suggests that iPGE2 also controls the activity of RARE in PC3
cells through EGFR-independent mechanisms. Further experiments
should be done to test this hypothesis.
As indicated above, 16,16-PGE2 itself is able to increase the lucifer-
ase activity of the RAREβ and RARβ promoter constructs in 3 different
cell lines without any concurrent treatment with ATRA. This is a strik-
ing ﬁnding because activation of RARE requires the binding of ATRA-
activated RAR-RXR heterodimers [7]. Data from cultured keratinocytes
may help to explain these results. These cells maintain steady state
intracellular ATRA concentrations in the 20–50 nM range [27] when
Fig. 5. EGFR transactivation by iPGE2-activated EPR results in RARE activation in the RARβ
promoter leading to increased RARβ expression. Role in PGE2- and ATRA-induced
transcriptional up-regulation of HIF-1α and production of renoprotective factor VEGF-A
(model of a proposed pathway).
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bovine serum) and no detectable ATRA (less than nM). ATRA was syn-
thesized from substrates derived from intracellular ester stores of reti-
nol [27]. On the other hand, treatment with ATRA determines a
dose-dependent increase in the activity of a RARE construct in cultured
keratinocytes and reaches its maximum (ﬁve-fold over control values)
at 10 μM ATRA [28]. These results are not in good agreement with the
fact that ATRA binds RARs with Ki b20 nM [8]. It indicates that activa-
tion of RAR-RXR by endogenousATRA is suboptimal and that full activa-
tion of RAR-RXR requires intracellular ATRA concentrations well above
those needed to bind RARs. This suggests that, at least in cultured
keratinocytes, treatmentwith ATRAmay activate anunknown signaling
pathway to reach the full activation of RAR-RXR. Our results in HK-2cells could help to identify this pathway, if we assume that their intra-
cellular ATRA content is similar to that of cultured keratinocytes (there-
by allowing the activation of RAR-RXR). In these conditions, the fact that
16,16-PGE2 treatment increases the activity of RAREβ and RARβ pro-
moter constructs to the same extent that ATRA treatment, suggests
that full activation of RAR-RXR requires iPGE2-induced EGFR trans-
activation. Further studies are needed to conﬁrm this hypothesis.
Regarding the transactivation of EGFR by iPGE2, in recent years it has
been reported transactivation of plasma membrane EGFR by PGE2-
activated EPR [29]. These ﬁndings are just a particular case of activation
of EGFR by plasma membrane G-protein coupled receptors (GPCR)
[30–32]. Our results suggest that transactivation of EGFR is not due to
plasma membrane EPR activated by extracellular PGE2 but to iPGE2-
activated intracellular EPR. However, intracellular EPR might be also
GPCR. In fact, it has been proposed that the distinct localization of EPR
and other GPCR may dictate different signaling pathways for the same
receptor [33]. On the other hand, two particular results involving partial
prevention of EGFR transactivation in our experimental setting deserve
a more detailed analysis. In the ﬁrst place, EP4 receptor antagonist
GW627368Xdid not fully preventATRA-induced EGFR phosphorylation
(while it abolished 16,16-PGE2-induced EGFR phosphorylation, as
shown in Fig. 3b). This suggests that ATRA transactivates EGFR through
additional mechanisms to the ones mediated by EPR. The other partial
prevention of EGFR phosphorylation was found in cells which were
treatedwith the inhibitor of prostaglandin uptake BGprior to treatment
with 16,16-PGE2 (Fig. 3b). This result should be conciliatedwith the fact
that the residual activation of EGFRwas not able to activate the RARE in
the RARβ promoter (and, therefore, to trigger RARβ-dependent HRE
activation leading to HIF-1α-dependent increase in VEGF-A produc-
tion). Our hypothesis to conciliate these results relies on the facts that
the expression of phosphorylated EGFR (Fig. 3a) was ubiquitous in
HK-2 cells (instead of being restricted to the plasma cell membrane)
and it increased upon treatment with 16,16-PGE2. We propose that
treatmentwith 16,16-PGE2 transactivates EGFR located at the cell mem-
brane as well as EGFR located inside the cell, but only transactivation of
intracellular EGFR results in RARE activation. In thisway, the residual ac-
tivation of EGFR after treatmentwith BGwould be due to transactivation
of EGFR located at the cell membrane and, therefore, it would not result
in RARE activation. However, speciﬁc experiments should verify this
hypothesis.
Whatever the mechanisms involved in the transactivation of EGFR
by ATRA and PGE2, the resulting increase in EGFR kinase activity
appears to be critical for RARβ up-regulation since ATRA- or 16,16-
PGE2-induced increase in RARβ expression was prevented by inhibi-
tion of EGFR kinase activity with AG1478 (Fig. 3). Regarding the path-
way downstream EGFR, histone H3 is one possible target. The
phosphorylation of histone H3 is functionally liked to the activation
of RARβ promoter by retinoids, so that it has been proposed as a mo-
lecular signature of this activation [34]. Since EGFR phosphorylates
and activates a number of important signaling molecules including ki-
nases [29], it is conceivable that the phosphorylation of histone H3
may result from the transactivation of EGFR by iPGE2-activated EPR.
It is important to conﬁrm this hypothesis in further studies because
up-regulation of RAR genes by ATRA presumably plays a critical role
in amplifying the genomic response to ATRA [10].
Current data provide evidence for the regulation of VEGF expression
by EGFR via theMAPK and PI3K signaling cascades and at least three dif-
ferent transcription factors, signal transducer and activator of transcrip-
tion 3 (STAT3), Sp1 andHIF [35]. Our results here are in good agreement
with this evidence since they indicate that the activation of EGFR by
16,16-PGE2 or ATRA (Fig. 3) results in AG1478-sensitive increased ex-
pression of HIF-1α/VEGF (Fig. 4). HIF-1α protein accumulates during
hypoxia through a very well know transcription-independent pathway.
It involves the stabilization of HIF-1α protein through inhibition of
proline hydroxylation at Pro402 and Pro564, which prevents pVHL-
dependent HIF-1α ubiquitination leading to proteasomal degradation
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under normoxia is not due to the increase HIF-1α protein stability
[11,13]. Since the effect of PGE2 and ATRA on HIF-1α expression is
prevented by actinomycin D, it is more likely that transcriptionalmech-
anisms are involved in the iPGE2-dependent up-regulation of HIF-1α
induced by these agents [11,13]. This suggestion is reinforced by the
fact that treatment with PGE2 resulted in the up-regulation of HIF-1α
mRNA in a BG-sensitive manner (Fig. 4a). Because the RARβ inhibitor
LE135 also prevented PGE2-induced increase in HIF-1α mRNA, the re-
sults shown in Fig. 4a are in good agreement with the view that iPGE2
enhances HIF-1α expression through RARβ-dependent transcriptional
mechanisms.
In the ﬁnal stage of the pathway studied by us, iPGE2-induced
HIF-1α up-regulation leads to increased production of VEGF-A, presum-
ably through activation of the HRE in its gene promoter (Figs. 4c, d, and
5). VEGF-A has protective effects in human renal proximal tubular cells
[37], in chronic renal disease [38] and in experimental models of renal
disease [39–41]. The regulation of ATRA- and 16,16-PGE2-induced
VEGF-A production by iPGE2-dependent EGFR transactivation opens
the way to new pharmacological approaches for the therapeutic modu-
lation of HIF-1α/VEGF-A.Acknowledgements
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